PORTFOLIO
Rivus Pharmaceuticals
-
YEAR
2022
-
STATUS
Active
Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health. The company’s pipeline of oral therapies includes HU6, a potential best-in-class oral therapy advancing in Phase 2 for MASH, and RV-8451, the first muscle-preserving, oral GLP-1 in IND-enabling studies for obesity.